High dose vitamin C as an adjuvant therapy in patient with septic shock

Phase 2

Recruiting

• Conditions: Patient with septic shock; septic shock, vitamin c, ascorbic acid

• Registration Number: TCTR20180925004
• Lead Sponsor: Bhumibol Adulyadej Hospital Fund

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2018-09-25
• Study Completion: 2019-09-26
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

1. Age over 18 year-old and less than 80 year-old
2. Septic shock is diagnosed in ER. (SIRS criteria ≥2 or qSOFA ≥2, require vasopressor for keeping MAP > 65 mmHg and serum lactate > 2 mmol/L)

Exclusion Criteria

1. Can not start intervention within 24 hours after septic shock is diagnosed
2. Prior antioxidant use eg. N-acetylcysteine, vitamin E, selenium, coenzyme Q10
3. There are contraindications for intravenous vitamin C (Allergic to vitamin C, bilateral ureteric obstruction, chronic hemodialysis, iron overload, oxalate stone former, hemochromatosis, G6PD deficiency and sickle cell disease)
4. Pregnant or breastfeeding woman
5. Patient who survives following CPR
6. Palliative care patients
7. Patients who will be enrolled in this study previously.
8. Patients who will be enrolled in other drug trials within 30 days before enrolment in this study

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
28-day all cause mortality 28 days visit in person, telephone contact

Secondary Outcome Measures

Name	Time	Method
Severity changing 4 days SOFA score